Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cartesian Therapeutics, Inc. Director's Dealing 2022

Jan 5, 2022

33483_dirs_2022-01-05_fab90dba-0a19-4225-9dc0-96a368a19a49.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2022-01-03

Reporting Person: BARABE TIMOTHY C (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-01-03 Stock Option (Right to Buy) $3.31 A 40000 Acquired 2032-01-02 Common Stock (40000.0) Direct

Footnotes

F1: The shares of Common Stock underlying this award will vest in full on January 3, 2023.